{
    "id": 1228,
    "fullName": "IDH1 R132H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "IDH1 R132H lies within the active site of the Idh1 protein (PMID: 19228619). R132H results in decreased conversion of isocitrate to alpha-ketoglutarate by Idh1, but also confers a gain of function to Idh1, as indicated by increased conversion of alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) in cell culture and in vitro assays, and is associated with increased 2HG levels in patient samples (PMID: 19935646, PMID: 23731180).",
            "references": [
                {
                    "id": 12562,
                    "pubMedId": 23731180,
                    "title": "Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23731180"
                },
                {
                    "id": 486,
                    "pubMedId": 19228619,
                    "title": "IDH1 and IDH2 mutations in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19228619"
                },
                {
                    "id": 487,
                    "pubMedId": 19935646,
                    "title": "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19935646"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3417,
        "geneSymbol": "IDH1",
        "terms": [
            "IDH1",
            "HEL-216",
            "HEL-S-26",
            "IDCD",
            "IDH",
            "IDP",
            "IDPC",
            "PICD"
        ]
    },
    "variant": "R132H",
    "createDate": "07/31/2014",
    "updateDate": "10/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 143853,
        "transcript": "NM_005896",
        "gDna": "chr2:g.208248388C>T",
        "cDna": "c.395G>A",
        "protein": "p.R132H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10936,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132H in culture (PMID: 28232670).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 5698,
                "therapyName": "BAY1436032",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8943,
                    "pubMedId": 28232670,
                    "title": "Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28232670"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 3078,
                "name": "grade III astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 493,
                    "pubMedId": 24077805,
                    "title": "5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24077805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5180,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Zolinza (vorinostat) in culture, demonstrating increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13756,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH1 R132H is diagnostic and aids in the diagnosis of gliomas (NCCN.org).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5230,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3784,
                "therapyName": "AGI-5198 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9939,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2071,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 2569,
                "therapyName": "AGI-5198",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2552,
                    "pubMedId": 23558169,
                    "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23558169"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20773,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H were sensitive to treatment with Lynparza (olaparib) in culture, demonstrating decreased colony formation (PMID: 29339439).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18038,
                    "pubMedId": 29339439,
                    "title": "IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29339439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9755,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 5194,
                "therapyName": "BPTES",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7525,
                    "pubMedId": 21045145,
                    "title": "Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21045145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21210,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Valproic Acid in culture, demonstrating increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1076,
                "therapyName": "Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13075,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AG-881 treatment decreased brain tumor 2HG levels in an orthotopic glioma cell line xenograft model harboring IDH1 R132H (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 2995,
                "therapyName": "AG-881",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10950,
                    "pubMedId": null,
                    "title": "Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/B126"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9948,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16889,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1491,
                "therapyName": "Ivosidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11753,
                    "pubMedId": 29860938,
                    "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860938"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15476,
                    "pubMedId": null,
                    "title": "Tibsovo (ivosidenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16896,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 1491,
                "therapyName": "Ivosidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11753,
                    "pubMedId": 29860938,
                    "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860938"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15476,
                    "pubMedId": null,
                    "title": "Tibsovo (ivosidenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 846,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3181,
                "name": "oligodendroglioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 490,
                    "pubMedId": 24077826,
                    "title": "Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24077826"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9937,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9946,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21208,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells expressing IDH1 R132H were resistant to treatment with Trichostatin (TSA) in culture, demonstrating decreased apoptotic activity and increased cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 2867,
                "therapyName": "Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9942,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9938,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9949,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 5324,
                "therapyName": "Cisplatin + Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AGI-5198 treatment in glioblastoma cells expressing IDH1 R132H led to decreased resistance to Trichostatin (TSA) treatment in culture, resulting in reduced cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 9638,
                "therapyName": "AGI-5198 + Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9950,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 5325,
                "therapyName": "AGI-5198 + Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5556,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3895,
                "therapyName": "AGI-5198 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4901,
                    "pubMedId": 26363012,
                    "title": "Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26363012"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring IDH1 R132H were sensitive to treatment with Talzenna (talazoparib) in culture, demonstrating decreased colony formation (PMID: 29339439).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18038,
                    "pubMedId": 29339439,
                    "title": "IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29339439"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21212,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AGI-5198 treatment in glioblastoma cells expressing IDH1 R132H led to decreased resistance to Zolinza (vorinostat) treatment in culture, resulting in reduced cell viability (PMID: 31151327).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 9639,
                "therapyName": "AGI-5198 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18479,
                    "pubMedId": 31151327,
                    "title": "IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151327"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3237,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",
            "molecularProfile": {
                "id": 1253,
                "profileName": "IDH1 R132H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7797,
                    "pubMedId": 28148839,
                    "title": "2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28148839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17365,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).",
            "molecularProfile": {
                "id": 32521,
                "profileName": "FLT3 D835Y IDH1 R132H"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).",
            "molecularProfile": {
                "id": 32521,
                "profileName": "FLT3 D835Y IDH1 R132H"
            },
            "therapy": {
                "id": 8466,
                "therapyName": "AGI-5198 + Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17364,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).",
            "molecularProfile": {
                "id": 32521,
                "profileName": "FLT3 D835Y IDH1 R132H"
            },
            "therapy": {
                "id": 2569,
                "therapyName": "AGI-5198",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15390,
                    "pubMedId": 30651561,
                    "title": "Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30651561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1253,
            "profileName": "IDH1 R132H",
            "profileTreatmentApproaches": [
                {
                    "id": 4027,
                    "name": "IDH1 Inhibitor",
                    "profileName": "IDH1 R132H"
                },
                {
                    "id": 17006,
                    "name": "IDH1 R132H peptide vaccine",
                    "profileName": "IDH1 R132H"
                },
                {
                    "id": 17007,
                    "name": "PEPIDH1M vaccine",
                    "profileName": "IDH1 R132H"
                },
                {
                    "id": 4026,
                    "name": "IDH Inhibitor (Pan)",
                    "profileName": "IDH1 R132H"
                }
            ]
        },
        {
            "id": 32521,
            "profileName": "FLT3 D835Y IDH1 R132H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 143853,
            "transcript": "NM_005896",
            "gDna": "chr2:g.208248388C>T",
            "cDna": "c.395G>A",
            "protein": "p.R132H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 143855,
            "transcript": "NM_001282387",
            "gDna": "chr2:g.208248388C>T",
            "cDna": "c.395G>A",
            "protein": "p.R132H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 143854,
            "transcript": "NM_001282386",
            "gDna": "chr2:g.208248388C>T",
            "cDna": "c.395G>A",
            "protein": "p.R132H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}